SVT 1D167
Alternative Names: SVT-1D167; SVT-1D167 + immunosuppressantsLatest Information Update: 04 Feb 2021
At a glance
- Originator Servatus Biopharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 03 Feb 2021 Servatus Biopharmaceuticals holds published patents in World, China and Singapore, and pending applications in Europe, Canada, Japan, USA and Australia, related to microbial biotherapeutics for the treatment of various indications, including gastrointestinal and inflammatory diseases, prior to February 2021
- 03 Feb 2021 Preclinical trials in Inflammatory bowel diseases in Australia (Servatus Biopharmaceuticals pipeline, February 2021)
- 03 Feb 2021 Preclinical trials in Psoriasis in Australia (Servatus Biopharmaceuticals pipeline, February 2021)